A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease
Identifieur interne : 005961 ( Main/Curation ); précédent : 005960; suivant : 005962A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease
Auteurs : G. K. Wenning [Royaume-Uni] ; M. T. O'Connell [Royaume-Uni] ; P. N. Patsalos [Royaume-Uni] ; Quinn [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 1995-09.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Antibiotique, Homme.
English descriptors
- KwdEn :
- 3,4-Dihydroxyphenylacetic Acid (metabolism), Agonist, Antibiotic, Antiparkinson agent, Antitubercular Agents (pharmacokinetics), Antitubercular Agents (therapeutic use), Antituberculous agent, Antituberculous therapy, Case study, Dopa Decarboxylase (metabolism), Dopa decarboxylase, Dopamine, Drug interaction, Homovanillic Acid (metabolism), Human, Humans, Idiopathic, Isoniazid, Isoniazid (pharmacokinetics), Isoniazid (therapeutic use), Levodopa, Levodopa (blood), Levodopa (metabolism), Levodopa (therapeutic use), Lung, Male, Middle Aged, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Pharmacokinetic interaction, Pharmacokinetics, Rifampin (pharmacokinetics), Rifampin (therapeutic use), Treatment, Tuberculosis, Tuberculosis, Pulmonary (complications), Tuberculosis, Pulmonary (drug therapy).
- MESH :
- chemical , blood : Levodopa.
- chemical , metabolism : 3,4-Dihydroxyphenylacetic Acid, Dopa Decarboxylase, Homovanillic Acid, Levodopa.
- chemical , pharmacokinetics : Antitubercular Agents, Isoniazid, Rifampin.
- chemical , therapeutic use : Antitubercular Agents, Isoniazid, Levodopa, Rifampin.
- complications : Parkinson Disease, Tuberculosis, Pulmonary.
- drug therapy : Parkinson Disease, Tuberculosis, Pulmonary.
- Humans, Male, Middle Aged.
Abstract
We studied the relationship between levodopa response and antituberculous treatment in a patient with idiopathic Parkinson's disease whose parkinsonism deteriorated when treatment with rifampicin and isoniazid (Rifinah) for pulmonary tuberculosis was started. A levodopa challenge test with regular recording of motor function was performed during, and again after stopping, antituberculous treatment. Plasma levodopa and levodopa metabolite pharmacokinetic profiles were determined using standard techniques. “On” period duration was 75% longer after antituberculous treatment had been stopped. These clinical findings correlated with a 37% increase in area under the concentration versus time curve (AUC), a 103% increase in apparent elimination half‐life (t1/2), a 41% increase in time to maximum concentration (Tmax), and a 33% decrease in maximum concentration (Cmax) of levodopa. A concurrent increase in plasma 3‐O‐methyldopa (3‐OMD) and a decrease in plasma 3,4‐dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), the three major metabolites of levodopa, suggests an inhibition of the enzyme dopa decarboxylase, probably by isoniazid.
Url:
DOI: 10.1002/mds.870100521
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003074
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :003074
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003D92
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004924
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :004924
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :004A35
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :004A59
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :004A59
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :004A59
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :008B23
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003460
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :003364
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003539
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :008C36
Links to Exploration step
ISTEX:2B182C53071FAD8B27970D365F3CFD62535276F4Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease</title>
<author><name sortKey="Wenning, G K" sort="Wenning, G K" uniqKey="Wenning G" first="G. K." last="Wenning">G. K. Wenning</name>
</author>
<author><name sortKey="O Connell, M T" sort="O Connell, M T" uniqKey="O Connell M" first="M. T." last="O'Connell">M. T. O'Connell</name>
</author>
<author><name sortKey="Patsalos, P N" sort="Patsalos, P N" uniqKey="Patsalos P" first="P. N." last="Patsalos">P. N. Patsalos</name>
</author>
<author><name sortKey="Quinn" sort="Quinn" uniqKey="Quinn" last="Quinn">Quinn</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:2B182C53071FAD8B27970D365F3CFD62535276F4</idno>
<date when="1995" year="1995">1995</date>
<idno type="doi">10.1002/mds.870100521</idno>
<idno type="url">https://api.istex.fr/document/2B182C53071FAD8B27970D365F3CFD62535276F4/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003074</idno>
<idno type="wicri:Area/Istex/Curation">003074</idno>
<idno type="wicri:Area/Istex/Checkpoint">003D92</idno>
<idno type="wicri:doubleKey">0885-3185:1995:Wenning G:a:clinical:and</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:8552121</idno>
<idno type="wicri:Area/PubMed/Corpus">004924</idno>
<idno type="wicri:Area/PubMed/Curation">004924</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004A35</idno>
<idno type="wicri:Area/Ncbi/Merge">004A59</idno>
<idno type="wicri:Area/Ncbi/Curation">004A59</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004A59</idno>
<idno type="wicri:doubleKey">0885-3185:1995:Wenning G:a:clinical:and</idno>
<idno type="wicri:Area/Main/Merge">008B23</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:95-0525299</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003460</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003364</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003539</idno>
<idno type="wicri:doubleKey">0885-3185:1995:Wenning G:a:clinical:and</idno>
<idno type="wicri:Area/Main/Merge">008C36</idno>
<idno type="wicri:Area/Main/Curation">005961</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease</title>
<author><name sortKey="Wenning, G K" sort="Wenning, G K" uniqKey="Wenning G" first="G. K." last="Wenning">G. K. Wenning</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>University Department of Clinical Neurology, Institute of Neurology, London</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="O Connell, M T" sort="O Connell, M T" uniqKey="O Connell M" first="M. T." last="O'Connell">M. T. O'Connell</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>University Department of Clinical Neurology, Institute of Neurology, London</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Patsalos, P N" sort="Patsalos, P N" uniqKey="Patsalos P" first="P. N." last="Patsalos">P. N. Patsalos</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>University Department of Clinical Neurology, Institute of Neurology, London</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Quinn" sort="Quinn" uniqKey="Quinn" last="Quinn">Quinn</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>University Department of Clinical Neurology, Institute of Neurology, London</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1995-09">1995-09</date>
<biblScope unit="vol">10</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="664">664</biblScope>
<biblScope unit="page" to="667">667</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">2B182C53071FAD8B27970D365F3CFD62535276F4</idno>
<idno type="DOI">10.1002/mds.870100521</idno>
<idno type="ArticleID">MDS870100521</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>3,4-Dihydroxyphenylacetic Acid (metabolism)</term>
<term>Agonist</term>
<term>Antibiotic</term>
<term>Antiparkinson agent</term>
<term>Antitubercular Agents (pharmacokinetics)</term>
<term>Antitubercular Agents (therapeutic use)</term>
<term>Antituberculous agent</term>
<term>Antituberculous therapy</term>
<term>Case study</term>
<term>Dopa Decarboxylase (metabolism)</term>
<term>Dopa decarboxylase</term>
<term>Dopamine</term>
<term>Drug interaction</term>
<term>Homovanillic Acid (metabolism)</term>
<term>Human</term>
<term>Humans</term>
<term>Idiopathic</term>
<term>Isoniazid</term>
<term>Isoniazid (pharmacokinetics)</term>
<term>Isoniazid (therapeutic use)</term>
<term>Levodopa</term>
<term>Levodopa (blood)</term>
<term>Levodopa (metabolism)</term>
<term>Levodopa (therapeutic use)</term>
<term>Lung</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Pharmacokinetic interaction</term>
<term>Pharmacokinetics</term>
<term>Rifampin (pharmacokinetics)</term>
<term>Rifampin (therapeutic use)</term>
<term>Treatment</term>
<term>Tuberculosis</term>
<term>Tuberculosis, Pulmonary (complications)</term>
<term>Tuberculosis, Pulmonary (drug therapy)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>3,4-Dihydroxyphenylacetic Acid</term>
<term>Dopa Decarboxylase</term>
<term>Homovanillic Acid</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antitubercular Agents</term>
<term>Isoniazid</term>
<term>Rifampin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antitubercular Agents</term>
<term>Isoniazid</term>
<term>Levodopa</term>
<term>Rifampin</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
<term>Tuberculosis, Pulmonary</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
<term>Tuberculosis, Pulmonary</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Agoniste</term>
<term>Antibiotique</term>
<term>Antiparkinsonien</term>
<term>Antituberculeux</term>
<term>Dopamine</term>
<term>Etude cas</term>
<term>Homme</term>
<term>Idiopathique</term>
<term>Interaction médicamenteuse</term>
<term>Isoniazide</term>
<term>Lévodopa</term>
<term>Mâle</term>
<term>Parkinson maladie</term>
<term>Pharmacocinétique</term>
<term>Poumon</term>
<term>Rifampicine</term>
<term>Traitement</term>
<term>Tuberculose</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Antibiotique</term>
<term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We studied the relationship between levodopa response and antituberculous treatment in a patient with idiopathic Parkinson's disease whose parkinsonism deteriorated when treatment with rifampicin and isoniazid (Rifinah) for pulmonary tuberculosis was started. A levodopa challenge test with regular recording of motor function was performed during, and again after stopping, antituberculous treatment. Plasma levodopa and levodopa metabolite pharmacokinetic profiles were determined using standard techniques. “On” period duration was 75% longer after antituberculous treatment had been stopped. These clinical findings correlated with a 37% increase in area under the concentration versus time curve (AUC), a 103% increase in apparent elimination half‐life (t1/2), a 41% increase in time to maximum concentration (Tmax), and a 33% decrease in maximum concentration (Cmax) of levodopa. A concurrent increase in plasma 3‐O‐methyldopa (3‐OMD) and a decrease in plasma 3,4‐dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), the three major metabolites of levodopa, suggests an inhibition of the enzyme dopa decarboxylase, probably by isoniazid.</div>
</front>
</TEI>
<double idat="0885-3185:1995:Wenning G:a:clinical:and"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease</title>
<author><name sortKey="Wenning, G K" sort="Wenning, G K" uniqKey="Wenning G" first="G. K." last="Wenning">G. K. Wenning</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Inst. neurology, univ. dep. clin. neurology</s1>
<s2>London WC1N 3BG</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>London WC1N 3BG</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="O Connell, M T" sort="O Connell, M T" uniqKey="O Connell M" first="M. T." last="O'Connell">M. T. O'Connell</name>
</author>
<author><name sortKey="Patsalos, P N" sort="Patsalos, P N" uniqKey="Patsalos P" first="P. N." last="Patsalos">P. N. Patsalos</name>
</author>
<author><name sortKey="Quinn, N P" sort="Quinn, N P" uniqKey="Quinn N" first="N. P." last="Quinn">N. P. Quinn</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">95-0525299</idno>
<date when="1995">1995</date>
<idno type="stanalyst">PASCAL 95-0525299 INIST</idno>
<idno type="RBID">Pascal:95-0525299</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003460</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003364</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003539</idno>
<idno type="wicri:doubleKey">0885-3185:1995:Wenning G:a:clinical:and</idno>
<idno type="wicri:Area/Main/Merge">008C36</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease</title>
<author><name sortKey="Wenning, G K" sort="Wenning, G K" uniqKey="Wenning G" first="G. K." last="Wenning">G. K. Wenning</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Inst. neurology, univ. dep. clin. neurology</s1>
<s2>London WC1N 3BG</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>London WC1N 3BG</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="O Connell, M T" sort="O Connell, M T" uniqKey="O Connell M" first="M. T." last="O'Connell">M. T. O'Connell</name>
</author>
<author><name sortKey="Patsalos, P N" sort="Patsalos, P N" uniqKey="Patsalos P" first="P. N." last="Patsalos">P. N. Patsalos</name>
</author>
<author><name sortKey="Quinn, N P" sort="Quinn, N P" uniqKey="Quinn N" first="N. P." last="Quinn">N. P. Quinn</name>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1995">1995</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Antibiotic</term>
<term>Antiparkinson agent</term>
<term>Antituberculous agent</term>
<term>Case study</term>
<term>Dopamine</term>
<term>Drug interaction</term>
<term>Human</term>
<term>Idiopathic</term>
<term>Levodopa</term>
<term>Lung</term>
<term>Male</term>
<term>Parkinson disease</term>
<term>Pharmacokinetics</term>
<term>Treatment</term>
<term>Tuberculosis</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Idiopathique</term>
<term>Tuberculose</term>
<term>Poumon</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Rifampicine</term>
<term>Antibiotique</term>
<term>Antituberculeux</term>
<term>Isoniazide</term>
<term>Etude cas</term>
<term>Traitement</term>
<term>Pharmacocinétique</term>
<term>Interaction médicamenteuse</term>
<term>Homme</term>
<term>Mâle</term>
<term>Agoniste</term>
<term>Dopamine</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Antibiotique</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease</title>
<author><name sortKey="Wenning, G K" sort="Wenning, G K" uniqKey="Wenning G" first="G. K." last="Wenning">G. K. Wenning</name>
</author>
<author><name sortKey="O Connell, M T" sort="O Connell, M T" uniqKey="O Connell M" first="M. T." last="O'Connell">M. T. O'Connell</name>
</author>
<author><name sortKey="Patsalos, P N" sort="Patsalos, P N" uniqKey="Patsalos P" first="P. N." last="Patsalos">P. N. Patsalos</name>
</author>
<author><name sortKey="Quinn" sort="Quinn" uniqKey="Quinn" last="Quinn">Quinn</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:2B182C53071FAD8B27970D365F3CFD62535276F4</idno>
<date when="1995" year="1995">1995</date>
<idno type="doi">10.1002/mds.870100521</idno>
<idno type="url">https://api.istex.fr/document/2B182C53071FAD8B27970D365F3CFD62535276F4/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003074</idno>
<idno type="wicri:Area/Istex/Curation">003074</idno>
<idno type="wicri:Area/Istex/Checkpoint">003D92</idno>
<idno type="wicri:doubleKey">0885-3185:1995:Wenning G:a:clinical:and</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:8552121</idno>
<idno type="wicri:Area/PubMed/Corpus">004924</idno>
<idno type="wicri:Area/PubMed/Curation">004924</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004A35</idno>
<idno type="wicri:Area/Ncbi/Merge">004A59</idno>
<idno type="wicri:Area/Ncbi/Curation">004A59</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004A59</idno>
<idno type="wicri:doubleKey">0885-3185:1995:Wenning G:a:clinical:and</idno>
<idno type="wicri:Area/Main/Merge">008B23</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease</title>
<author><name sortKey="Wenning, G K" sort="Wenning, G K" uniqKey="Wenning G" first="G. K." last="Wenning">G. K. Wenning</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>University Department of Clinical Neurology, Institute of Neurology, London</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="O Connell, M T" sort="O Connell, M T" uniqKey="O Connell M" first="M. T." last="O'Connell">M. T. O'Connell</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>University Department of Clinical Neurology, Institute of Neurology, London</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Patsalos, P N" sort="Patsalos, P N" uniqKey="Patsalos P" first="P. N." last="Patsalos">P. N. Patsalos</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>University Department of Clinical Neurology, Institute of Neurology, London</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Quinn" sort="Quinn" uniqKey="Quinn" last="Quinn">Quinn</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>University Department of Clinical Neurology, Institute of Neurology, London</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1995-09">1995-09</date>
<biblScope unit="vol">10</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="664">664</biblScope>
<biblScope unit="page" to="667">667</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">2B182C53071FAD8B27970D365F3CFD62535276F4</idno>
<idno type="DOI">10.1002/mds.870100521</idno>
<idno type="ArticleID">MDS870100521</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>3,4-Dihydroxyphenylacetic Acid (metabolism)</term>
<term>Antitubercular Agents (pharmacokinetics)</term>
<term>Antitubercular Agents (therapeutic use)</term>
<term>Antituberculous therapy</term>
<term>Dopa Decarboxylase (metabolism)</term>
<term>Dopa decarboxylase</term>
<term>Homovanillic Acid (metabolism)</term>
<term>Humans</term>
<term>Isoniazid</term>
<term>Isoniazid (pharmacokinetics)</term>
<term>Isoniazid (therapeutic use)</term>
<term>Levodopa</term>
<term>Levodopa (blood)</term>
<term>Levodopa (metabolism)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson's disease</term>
<term>Pharmacokinetic interaction</term>
<term>Rifampin (pharmacokinetics)</term>
<term>Rifampin (therapeutic use)</term>
<term>Tuberculosis, Pulmonary (complications)</term>
<term>Tuberculosis, Pulmonary (drug therapy)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>3,4-Dihydroxyphenylacetic Acid</term>
<term>Dopa Decarboxylase</term>
<term>Homovanillic Acid</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antitubercular Agents</term>
<term>Isoniazid</term>
<term>Rifampin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antitubercular Agents</term>
<term>Isoniazid</term>
<term>Levodopa</term>
<term>Rifampin</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
<term>Tuberculosis, Pulmonary</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
<term>Tuberculosis, Pulmonary</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We studied the relationship between levodopa response and antituberculous treatment in a patient with idiopathic Parkinson's disease whose parkinsonism deteriorated when treatment with rifampicin and isoniazid (Rifinah) for pulmonary tuberculosis was started. A levodopa challenge test with regular recording of motor function was performed during, and again after stopping, antituberculous treatment. Plasma levodopa and levodopa metabolite pharmacokinetic profiles were determined using standard techniques. “On” period duration was 75% longer after antituberculous treatment had been stopped. These clinical findings correlated with a 37% increase in area under the concentration versus time curve (AUC), a 103% increase in apparent elimination half‐life (t1/2), a 41% increase in time to maximum concentration (Tmax), and a 33% decrease in maximum concentration (Cmax) of levodopa. A concurrent increase in plasma 3‐O‐methyldopa (3‐OMD) and a decrease in plasma 3,4‐dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), the three major metabolites of levodopa, suggests an inhibition of the enzyme dopa decarboxylase, probably by isoniazid.</div>
</front>
</TEI>
</ISTEX>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005961 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 005961 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:2B182C53071FAD8B27970D365F3CFD62535276F4 |texte= A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease }}
This area was generated with Dilib version V0.6.23. |